These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10428260)

  • 1. An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy.
    Kahan BD
    Transplantation; 1999 Jul; 68(1):12-4. PubMed ID: 10428260
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mechanisms of nephrotoxic action of immunodepressants, calcineurine inhibitors].
    Nikitin AV
    Antibiot Khimioter; 2014; 59(1-2):44-7. PubMed ID: 25051716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: risk factors and strategies for prevention and treatment.
    Baran DA; Galin ID; Gass AL
    Am J Cardiovasc Drugs; 2004; 4(1):21-9. PubMed ID: 14967063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin inhibitors in pediatric renal transplant recipients.
    Filler G
    Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
    Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
    Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Function Changes Under Everolimus Plus Cyclosporine or Everolimus Plus Tacrolimus After Heart Transplantation.
    Chiang TY; Tsao CI; Wang SS
    Transplant Proc; 2018 Nov; 50(9):2756-2758. PubMed ID: 30401391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 8. Calcineurin-inhibitors in renal transplantation. Too precious to be abandoned.
    Ponticelli C
    Nephrol Dial Transplant; 2000 Sep; 15(9):1307-9. PubMed ID: 10978383
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
    Kaplinsky E; González-Costello J; Manito N; Roca J; Barbosa MJ; Nebot M; Salazar-Mendiguchia J; Berdejo J; Mañas P; Miralles A; Cequier A
    Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of calcineurin inhibitor nephrotoxicity in renal transplantation.
    Jacquet A; Francois H; Frangie C; Ahmad L; Charpentier B; Durrbach A
    Transpl Immunol; 2008 Nov; 20(1-2):29-31. PubMed ID: 18817870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitors in renal transplantation: what is the best option?
    Tanabe K
    Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil monotherapy in liver transplantation.
    Stewart SF; Hudson M; Talbot D; Manas D; Day CP
    Lancet; 2001 Feb; 357(9256):609-10. PubMed ID: 11558493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation.
    Vilalta R; Vila A; Nieto J; Callís L
    Transplant Proc; 2003 Mar; 35(2):703-4. PubMed ID: 12644102
    [No Abstract]   [Full Text] [Related]  

  • 14. Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation-A single center matched cohort study.
    Leiskau C; Rajanayagam J; Pfister ED; Goldschmidt I; Junge N; Karch A; Lerch C; Richter N; Lehner F; Schrem H; Baumann U
    Pediatr Transplant; 2018 Aug; 22(5):e13207. PubMed ID: 29729061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors.
    Niel OR; Berthoux F; Albano L; Dahan P; Aoudia R; Gugenheim J; Cassuto E
    Transplant Proc; 2009 Oct; 41(8):3329-32. PubMed ID: 19857743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation.
    Arora-Gupta N; Davies P; McKiernan P; Kelly DA
    Pediatr Transplant; 2004 Apr; 8(2):145-50. PubMed ID: 15049794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation.
    Yessayan L; Shafiq A; Peterson E; Wells K; Hu Y; Williams LK; Lanfear D
    Transplant Proc; 2015 Dec; 47(10):2968-72. PubMed ID: 26707323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How should the immunosuppressive regimen be managed in patients with established chronic allograft failure?
    Danovitch GM
    Kidney Int Suppl; 2002 May; (80):68-72. PubMed ID: 11982816
    [No Abstract]   [Full Text] [Related]  

  • 20. [Topic calcineurin inhibitors].
    Fonseca E
    Med Clin (Barc); 2003 Mar; 120(7):255-6. PubMed ID: 12623001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.